ACTU

Actuate Therapeutics Inc

0.4752

Oct 23 • 3:59 PM ET -0.0410 (-7.94%)

0.5126

Aftermarket • 7:37 PM ET +0.0374 (7.87%)

Healthcare Biotechnology USA Nano NASD

Peers: LSTA ELTX ONCY CRDF RVMD VSTM TPST KZIA PMVP RFL

| Held by: VTI VXF IWC BUSM

Scroll to Statements

Index	-
Market Cap	11.41M
Enterprise Value	7.38M
Income	-20.45M
Sales	0.00M
Book/sh	0.04
Cash/sh	0.18
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Aug 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	11.54
P/C	2.58
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.25
Current Ratio	1.25
Debt/Eq	0.40
LT Debt/Eq	0.40
Option/Short	No / Yes

EPS (ttm)	-0.89
EPS next Y	-0.66
EPS next Q	-0.17
EPS this Y	31.45%
EPS next Y	8.72%
EPS next 5Y	13.33%
EPS past 3/5Y	-0.08% -
Sales past 3/5Y	- -
EPS Y/Y TTM	29.39%
Sales Y/Y TTM	-
EPS Q/Q	32.66%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	1.62% -

Insider Own	57.42%
Insider Trans	0.00%
Inst Own	14.17%
Inst Trans	-3.55%
ROA	-336.18%
ROE	-553.75%
ROIC	-1467.12%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-27.05%
SMA50	-50.88%
SMA200	-79.27%
Trades

Shs Outstand	24.01M
Shs Float	10.23M
Short Float	13.00%
Short Ratio	3.77
Short Interest	1.33M
52W High	7.90 -93.98%
52W Low	0.41 15.90%
Volatility	24.56% 21.97%
ATR (14)	0.13
RSI (14)	35.45
Beta	1.29
Rel Volume	0.73
Avg Volume	353.01K
Volume	256,184

Perf Week	-21.45%
Perf Month	-23.35%
Perf Quarter	-58.68%
Perf Half Y	-84.00%
Perf YTD	-92.24%
Perf Year	-93.45%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	10.25
Prev Close	0.52
Price	0.48
Change %	-7.94%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-26-25	Initiated	B. Riley Securities	Buy	$20
Apr-22-25	Initiated	Craig Hallum	Buy	$21
Mar-17-25	Initiated	H.C. Wainwright	Buy	$20

Sep-09-26 05:00PM	Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) -8.03% -8.73%
07:00AM	Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib (GlobeNewswire)
Jun-09-26 07:45AM	Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma (GlobeNewswire) +10.44%
Jun-01-26 07:00AM	Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer (GlobeNewswire)
May-11-26 07:00AM	Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program (GlobeNewswire) -9.85%
08:45AM	Loading…
May-06-26 08:45AM	Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors (GlobeNewswire)
Apr-14-26 08:45AM	Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +14.29%
Mar-24-26 07:00AM	Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers (ACCESSWIRE) -9.43%
Mar-09-26 08:45AM	Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors (GlobeNewswire)
Mar-04-26 05:00PM	Actuate Therapeutics to Present at The Citizens Life Sciences Conference (GlobeNewswire)
Feb-24-26 08:45AM	Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) +10.64%
Feb-06-26 01:58PM	Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y (Zacks)
Jan-21-26 08:45AM	Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers (GlobeNewswire) +5.40%
Jan-12-26 08:45AM	Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 (GlobeNewswire) -6.35%
Jan-06-26 08:45AM	Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers (GlobeNewswire) +5.05%
12:00PM	Loading…
Dec-24-25 12:00PM	Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Dec-18-25 08:45AM	Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 (GlobeNewswire)
Dec-15-25 08:45AM	Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma (GlobeNewswire) -8.78%
Nov-28-25 09:55AM	How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% (Zacks) +10.58%
Sep-22-25 08:45AM	Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months (GlobeNewswire) +6.78%
Sep-11-25 04:01PM	Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option (GlobeNewswire)
Sep-10-25 08:31AM	Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock (GlobeNewswire) -19.15%
Sep-09-25 04:07PM	Actuate Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +7.18%
Aug-06-25 08:45AM	Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer (GlobeNewswire) +11.76%
Jul-17-25 08:45AM	Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas (GlobeNewswire)
Jun-24-25 09:15AM	Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial (GlobeNewswire)
Jun-20-25 08:45AM	Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO (GlobeNewswire)
Jun-16-25 08:30AM	Actuate Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-03-25 09:15AM	Actuate Therapeutics shares highlights from KOL eventon elraglusib data (TipRanks) -7.93%
Jun-02-25 09:00AM	Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -11.01%
04:30PM	Loading…
May-31-25 04:30PM	Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire)
May-22-25 05:05PM	Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -8.01%
May-07-25 08:00AM	Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting (GlobeNewswire)
May-06-25 08:00AM	Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -6.88%
Apr-30-25 08:00AM	Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 (GlobeNewswire)
Apr-23-25 10:24AM	Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +5.63%
Apr-17-25 08:00AM	Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 (GlobeNewswire)
Mar-27-25 04:01PM	Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results (Business Wire) -5.25%
Mar-26-25 09:15AM	Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer (SeekingAlpha)
Feb-25-25 08:00AM	Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer (GlobeNewswire)
Feb-06-25 08:00AM	Actuate Therapeutics to Participate in Upcoming Investor Conferences in February (GlobeNewswire) -6.56%
Jan-07-25 08:00AM	Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer (GlobeNewswire)
Dec-17-24 08:28AM	Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -11.85%
Nov-26-24 08:00AM	Actuate Therapeutics to be Added to Russell 2000 Index (GlobeNewswire)
Nov-12-24 08:00AM	Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma (GlobeNewswire)
Oct-29-24 06:39PM	Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development (GlobeNewswire)
Sep-23-24 08:00AM	Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3 Inhibitor (GlobeNewswire) -8.89%
Sep-16-24 08:00AM	Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire)
Sep-11-24 08:00AM	Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas (GlobeNewswire)
Sep-09-24 08:00AM	Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma (GlobeNewswire)
Sep-05-24 09:10AM	Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-20-24 09:00AM	Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 (GlobeNewswire)
Aug-14-24 04:05PM	Actuate Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire) +6.27%
Aug-12-24 08:27PM	Actuate Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)
May-28-24 07:00AM	Actuate Therapeutics Files Registration Statement for Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCHMITT DANIEL M	President, CEO and Director	Aug 14 '26	Option Exercise	0.00	272,056	0	422,237	Aug 14 05:00 PM
SCHMITT DANIEL M	President, CEO and Director	Feb 13 '26	Option Exercise	0.00	272,055	0	272,055	Feb 13 06:10 PM
THOMSON TODD S	Director	Jan 05 '26	Sale	5.80	280,000	1,624,000	904,795	Jan 07 12:45 PM
Kairos Venture Partners II, L.	Affiliate	Dec 11 '25	Proposed Sale	7.60	280,000	2,128,000		Dec 11 04:22 PM

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Co-Founder & COODr. Andrew P. Mazar Ph.D.

Chief Financial OfficerMr. Paul J. Lytle CPA

Scientific Founder and AdvisorDr. Alan Kozikowski Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACTU

Actuate Therapeutics Inc

Upgrade your Finviz experience